State RI
Clinical Trials in Rhode Island
Rhode Island is home to a significant concentration of clinical research activity, with academic medical centers, community hospitals, and specialized research clinics serving as active trial sites across a broad range of medical conditions. The studies listed here have at least one enrolled site in Rhode Island and represent Phase 1 through Phase 4 research sponsored by NIH, pharmaceutical companies, device manufacturers, and independent investigators.
Right now ClinicalMetric tracks 65 actively recruiting studies with Rhode Island sites out of 65 registered in total. The busiest research areas in Rhode Island are Ulcerative Colitis, Malignant Solid Neoplasm, Advanced Solid Tumor. Leading sponsors running trials in the state include Rhode Island Hospital, National Cancer Institute (NCI), SWOG Cancer Research Network. By stage, Rhode Island trials break down as Phase 1 (11), Phase 2 (13), Phase 3 (25), Phase 4 (3).
All trial data is sourced directly from ClinicalTrials.gov and updated daily. Recruiting status, eligibility criteria, enrollment targets, and contact information are included for each study. Patients and caregivers should review the full eligibility criteria on each trial listing — or consult their treating physician — before contacting a study site.
Top Conditions in Rhode Island
Ulcerative Colitis (2)Malignant Solid Neoplasm (2)Advanced Solid Tumor (2)Sickle Cell Disease (2)Acute Myeloid Leukemia (2)Endometrial Cancer (2)Anatomic Stage IV Breast Cancer AJCC v8 (1)Estrogen Receptor Positive (1)HER2/Neu Negative (1)Progesterone Receptor Positive (1)Prognostic Stage IV Breast Cancer AJCC v8 (1)Elevated CA15-3 or CEA or CA27-29 (1)
Frequently Asked Questions — Clinical Trials in Rhode Island
How many clinical trials are currently recruiting in Rhode Island?
ClinicalMetric currently tracks 65 actively recruiting clinical trials with at least one location in Rhode Island. The total number of registered studies—including active but not currently enrolling trials—is 65. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in Rhode Island?
Rhode Island hosts clinical trials across a broad range of medical conditions, including Ulcerative Colitis, Malignant Solid Neoplasm, Advanced Solid Tumor, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout Rhode Island serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in Rhode Island?
To join a clinical trial in Rhode Island, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in Rhode Island maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in Rhode Island
NCT03150693 Phase 3
Recruiting
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With N...
Condition
B Acute Lymphoblastic Leukemia
Enrollment
303 pts
Location
United States, Canada
Sponsor
Alliance for Clinical Trials i
NCT05875168 Phase 1, Phase 2
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Condition
Advanced Solid Tumor
Enrollment
590 pts
Location
United States, Belgium, Canada
Sponsor
Daiichi Sankyo
NCT04978168 N/A
Recruiting
Opioid Treatment and Peer Recovery Support
Condition
Opioid-use Disorder
Enrollment
450 pts
Location
United States
Sponsor
Brown University
NCT06008197 Phase 3
Recruiting
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mort...
Condition
Heart Failure
Enrollment
5,200 pts
Location
United States, Argentina, Australia
Sponsor
Colorado Prevention Center
NCT07398443 N/A
Recruiting
Using Novel Behavioral Economic Measures to Characterize Dual Marijuana and Toba...
Condition
Behavioral Economics
Enrollment
120 pts
Location
United States
Sponsor
Brown University
NCT06435429 Phase 3
Recruiting
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in...
Condition
Metastatic HER2-positive Breast Cancer
Enrollment
550 pts
Location
United States, Australia, Austria
Sponsor
Jazz Pharmaceuticals
NCT04239573 N/A
Recruiting
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Assoc...
Condition
Pancreatic Neoplasm
Enrollment
770 pts
Location
United States, Canada, Puerto Rico
Sponsor
ECOG-ACRIN Cancer Research Gro
NCT04398628 N/A
Recruiting
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Condition
Hematologic Disorder
Enrollment
3,000 pts
Location
United States
Sponsor
American Thrombosis and Hemost
NCT06934525 N/A
Recruiting
Testing Delivery Modalities of Team-Based CBT for Pediatric Anxiety in Community...
Condition
Obsessive Compulsive Disorder (OCD)
Enrollment
501 pts
Location
United States
Sponsor
Bradley Hospital
NCT06317649 Phase 2
Recruiting
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute M...
Condition
Acute Myeloid Leukemia
Enrollment
147 pts
Location
United States, Puerto Rico
Sponsor
National Cancer Institute (NCI
NCT06959524 N/A
Recruiting
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Co...
Condition
Coronary Arterial Disease (CAD)
Enrollment
1,616 pts
Location
United States, Australia, China
Sponsor
Boston Scientific Corporation
NCT06264180 Phase 3
Recruiting
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on A...
Condition
Advanced Melanoma
Enrollment
400 pts
Location
United States, France, Germany
Sponsor
Replimune, Inc.
NCT04678154 Phase 3
Recruiting
Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fr...
Condition
Post Operative Surgical Site Infection
Enrollment
600 pts
Location
United States
Sponsor
Major Extremity Trauma Researc
NCT06318169 Phase 3
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With ...
Condition
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Enrollment
1,350 pts
Location
United States, Argentina, Australia
Sponsor
89bio, Inc.
NCT06546670 Phase 1, Phase 2
Recruiting
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Ce...
Condition
Sickle Cell Disease
Enrollment
161 pts
Location
United States, Turkey (Türkiye)
Sponsor
Novartis Pharmaceuticals
NCT06605118 Phase 3
Recruiting
Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial
Condition
Obstetrical Complications
Enrollment
8,000 pts
Location
United States
Sponsor
The George Washington Universi
NCT05544019 Phase 1
Recruiting
Study of SGR-1505 in Mature B-Cell Neoplasms
Condition
Mature B-Cell Neoplasm
Enrollment
98 pts
Location
United States, France, Italy
Sponsor
Schrödinger, Inc.
NCT06989112 Phase 3
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegos...
Condition
Endometrial Cancer
Enrollment
600 pts
Location
United States, Australia, Austria
Sponsor
AstraZeneca
NCT06958328 Phase 3
Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Condition
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma
Enrollment
356 pts
Location
United States, Canada
Sponsor
NRG Oncology
NCT05390892 Phase 4
Recruiting
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
Condition
Type2Diabetes
Enrollment
6,000 pts
Location
United States
Sponsor
Brigham and Women's Hospital
NCT05642611 Phase 3
Recruiting
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemo...
Condition
Malignant Solid Neoplasm
Enrollment
777 pts
Location
United States
Sponsor
SWOG Cancer Research Network
NCT06246916 Phase 3
Recruiting
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Partic...
Condition
Melanoma
Enrollment
560 pts
Location
United States, Canada
Sponsor
Regeneron Pharmaceuticals
NCT04743141 Phase 3
Recruiting
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatme...
Condition
Acute Treatment of Migraine
Enrollment
600 pts
Location
United States, Poland, Spain
Sponsor
Pfizer
NCT04005469 Phase 1, Phase 2
Recruiting
Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusio...
Condition
Ischemia Reperfusion Injury
Enrollment
20 pts
Location
United States
Sponsor
Rhode Island Hospital
NCT00358943 N/A
Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Preg...
Condition
Gaucher Disease
Enrollment
12,000 pts
Location
United States, Argentina, Australia
Sponsor
Genzyme, a Sanofi Company
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology